<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362">
  <stage>Registered</stage>
  <submitdate>2/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <actrnumber>ACTRN12605000384651</actrnumber>
  <trial_identification>
    <studytitle>CONSTA in Polynesian Subjects</studytitle>
    <scientifictitle>An observational study of the impact of long-acting risperidone microspheres on the symptom severity and functional recovery  in Maori and Pacific people with schizophrenia and related psychotic disorders</scientifictitle>
    <utrn />
    <trialacronym>CIPS</trialacronym>
    <secondaryid>RIS-SCH-4050</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Risperdal Consta injections as determined by the treating psychiatrist for up to two years.</interventions>
    <comparator />
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptomatic and functional improvement over a one year period</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Stability of improvement </outcome>
      <timepoint>On two year follow up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medication acceptability and side effects</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary disgnosis of schizophreniaUnder care of an ethnic specific service.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unable to give consent.Risperidone prescription contra-indicated.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>9/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Janssen-Cialg Research Fund</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor S W Miles</name>
      <address>Waitemata District Health Board
Private Bag 93503
Takapuna North Shore City</address>
      <phone>+64 9 4139734</phone>
      <fax>+64 9 4487133</fax>
      <email>wayne.miles@waitematadhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor S W Miles</name>
      <address>Waitemata District Health Board
Private Bag 93503
Takapuna North Shore City</address>
      <phone>+64 9 4139734</phone>
      <fax>+64 9 4487133</fax>
      <email>wayne.miles@waitematadhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>